Global Schistosomiasis Diseases Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Schistosomiasis Diseases Market Overview

The Schistosomiasis Diseases Market was valued at USD 81.89 million in 2025 and is projected to reach USD 112.07 million by 2033, growing at a CAGR of 4.00% from 2026 to 2033. The market is witnessing steady growth driven by the rising prevalence of parasitic infections in tropical and subtropical regions, increasing global health initiatives for neglected tropical diseases (NTDs), and growing investments in antiparasitic drug development and disease control programs.

The increasing burden of schistosomiasis across developing economies, particularly in parts of Africa, Asia-Pacific, and South America, combined with expanding awareness campaigns led by international health organizations, is encouraging governments and healthcare agencies to strengthen diagnosis, prevention, and treatment efforts. Mass drug administration (MDA) programs, improved access to praziquantel-based therapies, and advancements in diagnostic technologies are supporting market expansion. In addition, collaborations between pharmaceutical companies, non-governmental organizations, and public health agencies are accelerating research activities and improving treatment accessibility in endemic regions.

Key Market Trends & Insights

• North America dominated the Schistosomiasis Diseases Market with the largest revenue share of 36.42% in 2025, supported by strong pharmaceutical research capabilities, increasing funding for neglected tropical disease programs, and the presence of major healthcare organizations.
• The Schistosoma Mansoni segment led the market with a 46.82% share in 2025, driven by its widespread prevalence across Sub-Saharan Africa, the Middle East, and parts of South America.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.4% from 2026 to 2033, fueled by improving healthcare infrastructure, rising disease awareness, and expanding public health campaigns across China, India, and Southeast Asia.
• Schistosoma Japonicum are the fastest-growing type, projected to register a CAGR of 7.1%, reflecting the surge in disease monitoring programs and rising healthcare investments across Asia-Pacific regions.
• The Praziquantel segment dominated the drugs category with a 58.44% revenue share in 2025, led by high effectiveness, affordability, and widespread recommendation as the first-line treatment for schistosomiasis infections.
• Oral accounted for 67.39% of the market, preferred by widespread use of orally administered antiparasitic drugs such as praziquantel for large-scale treatment programs.
• The Oxamniquine segment is the fastest-growing drugs category, with a CAGR of 6.8%, driven by the increasing research activities focused on alternative therapeutic solutions for praziquantel-resistant infections.

Market Size & Forecast

• Global Market Value (2025): USD 81.89 Million
• Expected Market Value (2033): USD 112.07 Million
• Forecast CAGR (2026–2033): 4.00%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

Report Scope and Schistosomiasis Diseases Market Segmentation

Schistosomiasis Diseases Market Trends

Trend: Expansion of Neglected Tropical Disease Elimination Programs

Governments and international health organizations are increasingly expanding schistosomiasis control and elimination initiatives through mass drug administration campaigns, improved sanitation programs, and community-based awareness efforts across endemic regions. The integration of rapid diagnostic technologies enables earlier disease detection and more effective monitoring of infection rates in high-risk populations. Public health agencies and non-governmental organizations are similarly leveraging school-based treatment programs to improve healthcare access among vulnerable communities, while research collaborations are supporting the development of next-generation therapeutics and vaccine candidates targeting long-term disease prevention.

For instance, in January 2024, the World Health Organization expanded support for schistosomiasis elimination campaigns across several African countries through enhanced praziquantel distribution and community-based disease surveillance initiatives.

Schistosomiasis Diseases Market Dynamics

Key Market Driver: Rising Government and Global Health Investments in Disease Control

The growing global burden of schistosomiasis and other neglected tropical diseases has created substantial demand for effective treatment programs, rapid diagnostics, and preventive healthcare initiatives across endemic regions. Governments, non-governmental organizations, and international health agencies are deploying large-scale disease control programs as a core component of public health strategies, improving treatment accessibility, reducing infection rates, and strengthening healthcare infrastructure in underserved communities.

For instance, in March 2024, the Bill & Melinda Gates Foundation increased funding support for neglected tropical disease research programs focused on expanding schistosomiasis treatment accessibility and improving diagnostic capabilities in Sub-Saharan Africa.

Key Restraint/Challenge: Limited Healthcare Infrastructure in Endemic Regions

A significant restraint in the Schistosomiasis Diseases Market is the inadequate healthcare infrastructure across many endemic countries. Limited access to diagnostic facilities, insufficient healthcare workforce availability, and poor sanitation systems continue to restrict early disease detection and timely treatment implementation in rural and underserved populations. The overall challenge extends to inconsistent drug distribution networks, limited healthcare funding, and inadequate disease surveillance systems, making effective long-term disease management difficult for healthcare authorities and humanitarian organizations.

For instance, in September 2024, several healthcare agencies in East Africa reported persistent logistical and infrastructure challenges affecting large-scale schistosomiasis screening and treatment campaigns in remote communities.

Key Market Opportunity: Development of Advanced Diagnostic and Vaccine Technologies

The development of innovative diagnostic solutions and vaccine technologies presents a significant market opportunity. Advanced molecular testing platforms can improve early-stage disease identification, provide faster infection monitoring, and support more efficient management of community-wide treatment programs. The expansion of collaborative research initiatives and international funding programs is further accelerating vaccine development efforts, opening growth opportunities for biotechnology companies and pharmaceutical manufacturers across emerging healthcare markets in Africa, Asia-Pacific, and Latin America.

For instance, in June 2024, researchers supported by the European & Developing Countries Clinical Trials Partnership advanced clinical studies for new schistosomiasis vaccine candidates designed to improve long-term disease prevention outcomes.

Schistosomiasis Diseases Market Scope

The schistosomiasis diseases market is segmented on the basis of type, drugs, route of administration, end-users, and distribution channel.

• By Type

On the basis of type, the Schistosomiasis Diseases Market is segmented into Schistosoma Mansoni, Schistosoma Japonicum, and Others. The Schistosoma Mansoni segment dominated the market with a 46.82% share in 2025, owing to its widespread prevalence across Sub-Saharan Africa, the Middle East, and parts of South America. This species is one of the leading causes of intestinal schistosomiasis and contributes significantly to the global disease burden. Increasing government-led treatment campaigns and international eradication initiatives are supporting strong demand for diagnostic and therapeutic solutions targeting this infection type. The segment also benefits from extensive research funding and higher awareness among healthcare organizations. Rising adoption of praziquantel-based mass drug administration programs is further improving treatment accessibility in endemic areas. Continuous surveillance activities and public health investments continue to strengthen the dominance of this segment globally.

The Schistosoma Japonicum segment is projected to register the fastest growth at a CAGR of 7.1% from 2026 to 2033, driven by increasing disease monitoring programs and rising healthcare investments across Asia-Pacific regions. This infection type is associated with severe complications due to its high egg production and rapid transmission potential. Growing awareness regarding early diagnosis and preventive treatment is supporting market expansion. Governments and global health agencies are increasing focus on improving sanitation infrastructure and reducing waterborne disease transmission in endemic communities. Technological advancements in molecular diagnostic techniques are also enhancing detection accuracy for Schistosoma Japonicum infections. Increasing collaborations between regional healthcare authorities and research organizations are further accelerating growth opportunities for this segment.

• By Drugs

On the basis of drugs, the Schistosomiasis Diseases Market is segmented into Praziquantel, Metrifonate, Oxamniquine, and Others. The Praziquantel segment dominated the market with a 58.44% share in 2025 due to its high effectiveness, affordability, and widespread recommendation as the first-line treatment for schistosomiasis infections. The drug is extensively utilized in mass drug administration programs supported by governments and international health organizations across endemic countries. Its broad-spectrum antiparasitic activity and favorable safety profile have significantly strengthened adoption rates globally. Continuous support from the World Health Organization and non-governmental organizations has improved accessibility in low-income regions. Increasing pharmaceutical production and donation initiatives are also supporting consistent supply chains. The segment continues to benefit from growing public health campaigns focused on controlling neglected tropical diseases.

The Oxamniquine segment is expected to witness the fastest growth at a CAGR of 6.8% from 2026 to 2033, driven by increasing research activities focused on alternative therapeutic solutions for praziquantel-resistant infections. Rising concerns regarding drug resistance and treatment limitations are encouraging healthcare providers to explore complementary antiparasitic therapies. The segment is also benefiting from ongoing clinical studies evaluating combination treatment approaches for severe schistosomiasis cases. Expanding pharmaceutical research investments in tropical disease management are further supporting product development activities. Growing collaborations between biotechnology firms and academic institutions are accelerating innovation in antiparasitic drug formulations. Increasing demand for diversified treatment options is expected to contribute significantly to future segment growth.

• By Route of Administration

On the basis of route of administration, the Schistosomiasis Diseases Market is segmented into oral, topical, and others. The Oral segment dominated the market with a 67.39% share in 2025, owing to the widespread use of orally administered antiparasitic drugs such as praziquantel for large-scale treatment programs. Oral formulations offer convenient administration, improved patient compliance, and cost-effective distribution across community healthcare settings. These therapies are extensively used in school-based deworming campaigns and government-supported disease control programs. The segment also benefits from simplified storage, transportation, and mass distribution capabilities in remote endemic areas. Increasing investments in oral drug manufacturing and donation programs are further supporting accessibility. Strong preference for non-invasive treatment methods continues to reinforce the dominance of this segment globally.

The Others segment is projected to register the fastest growth at a CAGR of 6.7% from 2026 to 2033, driven by increasing research into advanced drug delivery technologies and novel therapeutic approaches. Healthcare providers and pharmaceutical companies are exploring innovative administration methods to improve treatment effectiveness and reduce side effects associated with conventional therapies. Expanding investments in biologics, targeted therapies, and combination treatment solutions are supporting segment development. Technological advancements in pharmaceutical formulation techniques are also improving drug absorption and therapeutic outcomes. Growing focus on personalized treatment approaches for severe infections is further contributing to segment growth. Rising clinical research activities and innovation in tropical disease therapeutics are expected to create new opportunities in this category.

• By End-Users

On the basis of end-users, the Schistosomiasis Diseases Market is segmented into hospitals, homecare, speciality centres, and others. The Hospitals segment dominated the market with a 49.76% share in 2025 due to the availability of advanced diagnostic facilities, skilled healthcare professionals, and structured infectious disease treatment programs. Hospitals serve as primary centers for severe schistosomiasis diagnosis, inpatient treatment, and long-term disease management in endemic regions. Increasing government healthcare expenditure and expansion of infectious disease units are supporting segment growth. The segment also benefits from greater accessibility to prescription medications and laboratory testing services. Rising hospitalization rates related to chronic parasitic infections are further strengthening demand for hospital-based care. Continuous improvements in healthcare infrastructure and disease surveillance systems continue to support market leadership.

The Speciality Centres segment is anticipated to witness the fastest growth at a CAGR of 7.0% from 2026 to 2033, driven by increasing demand for specialized infectious disease management and targeted parasitic treatment services. These centers provide focused expertise in tropical disease diagnosis, advanced laboratory testing, and community outreach programs. Growing investments in specialized healthcare facilities across emerging economies are supporting market expansion. Increasing awareness regarding early disease intervention and preventive healthcare is encouraging patient preference for dedicated treatment centers. Collaborations between public health organizations and specialty clinics are further improving healthcare accessibility in endemic communities. The segment is also benefiting from rising adoption of advanced diagnostic technologies and personalized disease management solutions.

• By Distribution Channel

On the basis of distribution channel, the Schistosomiasis Diseases Market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The Hospital Pharmacy segment dominated the market with a 52.18% share in 2025, owing to strong integration with hospital-based infectious disease treatment programs and direct access to prescription antiparasitic medications. Hospital pharmacies play a critical role in supporting large-scale treatment distribution and ensuring medication availability for inpatient and outpatient care. Increasing patient admissions related to parasitic infections are contributing to higher dispensing volumes through hospital channels. The segment also benefits from reliable pharmaceutical procurement systems and government-supported healthcare supply chains. Growing healthcare infrastructure development in endemic regions is further strengthening market penetration. Strong regulatory oversight and controlled drug distribution continue to support the dominance of this segment globally.

The Online Pharmacy segment is projected to register the fastest growth at a CAGR of 7.3% from 2026 to 2033, driven by increasing digital healthcare adoption and improving internet accessibility across developing regions. Online platforms provide convenient access to antiparasitic medications, especially in underserved and remote communities with limited physical pharmacy infrastructure. Rising use of telemedicine services and digital prescription platforms is further accelerating online pharmaceutical sales. The segment is also benefiting from expanding e-commerce healthcare investments and growing consumer preference for home-based medicine delivery services. Increasing smartphone penetration and digital health awareness are supporting broader adoption of online pharmacy channels. Continuous advancements in healthcare logistics and digital payment infrastructure are expected to create significant growth opportunities for this segment.

Schistosomiasis Diseases Market Regional Analysis

North America dominated the Schistosomiasis Diseases Market with the largest revenue share of 36.42% in 2025, supported by strong pharmaceutical research capabilities, increasing funding for neglected tropical disease programs, and the presence of major healthcare organizations. The region also benefits from advanced diagnostic infrastructure, high funding support from global health organizations, and growing research activities focused on antiparasitic therapies and vaccine development applications. Increasing focus on infectious disease surveillance and tropical disease prevention initiatives continues to strengthen North America’s leadership position in the global market.

U.S. Schistosomiasis Diseases Market Insight

The U.S. schistosomiasis diseases market is witnessing steady growth due to rising investments in neglected tropical disease research, infectious disease surveillance programs, and advanced diagnostic technologies. The country’s strong pharmaceutical and biotechnology ecosystem, along with increasing adoption of molecular diagnostics, AI-assisted disease monitoring, and innovative antiparasitic treatment solutions, is driving demand across healthcare and research applications. In addition, growing emphasis on global health initiatives and improving access to tropical disease treatment programs is accelerating market development across healthcare institutions and research organizations.

Europe Schistosomiasis Diseases Market Insight

The Europe schistosomiasis diseases market remains a major contributor to global revenue, driven by strong government support, expanding tropical disease research programs, and high demand for advanced diagnostic and therapeutic solutions. The widespread involvement of healthcare organizations, academic institutions, and pharmaceutical companies in neglected tropical disease management is supporting market expansion across the region. Increasing investments in vaccine development technologies, coupled with strong public health initiatives and skilled research capabilities, continue to enhance the adoption of schistosomiasis disease management solutions throughout Europe.

U.K. Schistosomiasis Diseases Market Insight

The U.K. schistosomiasis diseases market is experiencing steady growth, supported by rising adoption of advanced infectious disease diagnostic technologies, expanding tropical medicine research, and increasing government-backed healthcare initiatives. Increasing investments in pharmaceutical innovation and growing demand for effective and accessible antiparasitic treatment solutions are contributing to market growth. Furthermore, integration of molecular testing, AI-supported disease surveillance, and digital healthcare technologies is improving disease monitoring and treatment efficiency, positioning the U.K. as a key innovation hub in the schistosomiasis diseases industry.

Germany Schistosomiasis Diseases Market Insight

The Germany schistosomiasis diseases market is expanding steadily due to the country’s advanced healthcare infrastructure, strong pharmaceutical manufacturing capabilities, and increasing adoption of next-generation diagnostic technologies. Healthcare providers, research institutions, and biotechnology companies are increasingly focusing on schistosomiasis diagnosis, treatment development, and infectious disease research activities. Continuous advancements in molecular diagnostics, vaccine research, and targeted therapeutic technologies, along with strong government focus on public health innovation and disease prevention, are further driving market growth in Germany.

Asia-Pacific Schistosomiasis Diseases Market Insight

The Asia-Pacific schistosomiasis diseases market is expected to witness rapid growth, driven by increasing healthcare investments, expanding disease control programs, and rising public health awareness across countries such as China, India, and the Philippines. Growing awareness regarding waterborne parasitic diseases, rising adoption of advanced diagnostic technologies, and increasing demand for affordable and scalable treatment solutions are supporting regional market expansion. Additionally, the growing presence of pharmaceutical manufacturing facilities and tropical disease research centers is accelerating treatment accessibility across healthcare and community health sectors.

Japan Schistosomiasis Diseases Market Insight

The Japan schistosomiasis diseases market is witnessing consistent growth due to rising investments in infectious disease research, advanced healthcare technologies, and public health monitoring initiatives. Pharmaceutical companies, healthcare institutions, and research organizations are increasingly adopting advanced diagnostic systems for disease surveillance, treatment development, and epidemiological research purposes. Moreover, increasing integration of molecular testing technologies and the country’s focus on efficient and preventive healthcare solutions are further contributing to market growth.

China Schistosomiasis Diseases Market Insight

The China schistosomiasis diseases market is growing rapidly, driven by increasing government initiatives for disease elimination, expanding healthcare infrastructure, and rising focus on waterborne disease prevention programs. Growing adoption of AI-enabled diagnostic platforms and advanced infectious disease monitoring systems across healthcare and public health sectors is significantly boosting market demand. In addition, rising investments in pharmaceutical research, increasing awareness regarding early disease diagnosis, and rapid advancements in healthcare technologies are positioning China as one of the fastest-growing markets for schistosomiasis disease management globally.

Schistosomiasis Diseases Market Share

The schistosomiasis diseases industry is primarily led by well-established companies, including:

• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Bayer AG (Germany)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• Sanofi (France)
• Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Eli Lilly and Company (U.S.)
• Gilead Sciences, Inc. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Cipla Limited (India)
• Reddy’s Laboratories Ltd. (India)
• Lupin Limited (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma Limited (India)

Latest Developments in Schistosomiasis Diseases Market

• In December 2024, the World Health Organization’s Special Programme for Research and Training in Tropical Diseases (TDR), in collaboration with Tanzania’s National Institute for Medical Research, launched expanded community engagement initiatives to support the delivery of pediatric praziquantel treatment for schistosomiasis among children aged 2 to 5 years. The initiative focused on improving disease awareness, treatment accessibility, and preventive healthcare in endemic communities, strengthening global efforts toward schistosomiasis elimination
• In October 2024, the World Health Organization introduced updated guidance aimed at accelerating the elimination of schistosomiasis and intestinal helminthiasis through expanded preventive chemotherapy, improved disease surveillance, and integrated public health strategies. The guidance emphasized stronger access to praziquantel treatment, sanitation improvements, and enhanced monitoring systems across endemic countries
• In February 2024, global health stakeholders and healthcare organizations convened in Istanbul to strengthen country readiness for equitable access to new pediatric schistosomiasis treatment solutions. The initiative focused on improving healthcare delivery systems, regulatory preparedness, and coordinated implementation strategies for introducing advanced schistosomiasis therapies in endemic countries
• In January 2024, the World Health Organization’s TDR program announced support for the rollout of arpraziquantel, a new pediatric treatment for schistosomiasis recommended by the European Medicines Agency for preschool-aged children. The treatment was designed to improve therapeutic accessibility for children under six years old, addressing a major unmet need in schistosomiasis disease management across endemic regions
• In April 2023, researchers published the development of a novel gold immunochromatographic assay for Schistosoma japonicum diagnosis in Frontiers in Immunology, designed to improve rapid point-of-care testing and disease surveillance capabilities. The advanced diagnostic technology enhanced sensitivity and portability for schistosomiasis detection, supporting faster diagnosis and large-scale screening programs in resource-limited healthcare setting

SKU-54611